-+ 0.00%
-+ 0.00%
-+ 0.00%

Wedbush Maintains Outperform on Opus Genetics, Raises Price Target to $13

Benzinga·09/10/2026 12:57:43
Listen to the news
Wedbush analyst Yun Zhong maintains Opus Genetics (NASDAQ:IRD) with a Outperform and raises the price target from $10 to $13.